DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age
(Thomson Reuters ONE) -
Press Release
Montrouge, France,August 2, 2017
DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic
Patients One to Three Years of Age
Expansion of clinical program into younger children reinforces commitment to
developing potential treatments for patients suffering from peanut allergy
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced that the first patient has been enrolled in EPITOPE (EPIT
in TOddlers with PEanut Allergy), a global, Phase III clinical trial assessing
the safety and efficacy of Viaskin Peanut for the treatment of peanut-allergic
patients one to three years of age. Viaskin Peanut is the company's lead product
candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary
technology platform that delivers biologically active compounds to the immune
system through the skin.
"With results from our ongoing Phase III trial of Viaskin Peanut in peanut-
allergic children four to 11 years of age expected later this year, the launch
of EPITOPE, our second Viaskin Peanut Phase III program, highlights our
commitment to accelerating innovation in the field of food allergies," said Dr.
Hugh Sampson, Chief Scientific Officer of DBV Technologies, Director of the
Jaffe Food Allergy Institute at Mount Sinai, and the Kurt Hirschhorn Professor
of Pediatrics at the Icahn School of Medicine at Mount Sinai. "Recent studies in
the field suggest that treating patients from a younger age may lead to
significant therapeutic benefit, and Viaskin may be able to offer a safe,
effective and convenient treatment for these younger children."
EPITOPE is a two-part, pivotal, double-blind, placebo-controlled Phase III trial
designed to evaluate the safety and efficacy of Viaskin Peanut in children one
to three years of age. Part A of the trial will assess the safety of two doses
of Viaskin Peanut, 100 µg and 250 µg in approximately 50 patients for three
months. Based on the results from Part A, the highest safe dose will be studied
in Part B, which will enroll approximately 281 additional patients to evaluate
the safety and efficacy of the identified dose versus placebo for 12 months. The
primary efficacy endpoint of the study is based on a responder analysis after
12 months of treatment of Viaskin Peanut. Efficacy will be assessed using a
double-blind, placebo controlled food challenge (DBPCFC).
Dr. Wesley Burks, Curnen Professor of Pediatrics, University of North Carolina
School of Medicine, and Principal Investigator of the EPITOPE study, said:
"Seeing the first patient enrolled in this trial represents another important
step forward towards exploring treatments for patients suffering from peanut
allergy. We have seen an increase in the diagnosis of this disease within the
first few years of life, representing a high unmet medical need for these young
children."
About EPITOPE
EPITOPE is expected to enroll approximately 331 patients (50 in Part A and 281
in Part B) in approximately 20 - 40 centers across North America (Canada and the
United States), Ireland, and Australia.
The EPITOPE trial is a two-part trial: Part A is designed to assess the safety
of Viaskin Peanut 100 µg and 250 µg to determine the highest safe dose, and Part
B is designed to assess the safety and efficacy of the highest safe dose
selected in Part A. In Part A, patients are randomized 1:2:2 to receive either
placebo or Viaskin Peanut 100 mcg or 250 mcg for three months. A safety analysis
will be performed after three months to determine the highest safe dose to be
studied in Part B. If there are no safety concerns with either of the two doses,
patients will continue on their respective treatment and remain on the same
active dose or placebo they received in Part A. In Part B, patients will be
randomized 2:1 to receive the selected dose of Viaskin Peanut or placebo.
The primary endpoint is based on a responder analysis after 12 months of
treatment with the selected dose of Viaskin Peanut. Efficacy will be assessed
using a double-blind, placebo controlled food challenge (DBPCFC). For patients
with a baseline peanut protein eliciting dose (ED) equal to or less than 10 mg,
a responder is defined as a patient with a peanut protein ED equal to or greater
than 300 mg of peanut protein after 12 months of treatment. For patients with a
baseline ED greater than 10 mg, a responder is defined as a patient with a
peanut protein ED equal to or greater than 1,000 mg of peanut protein after 12
months of treatment. As a secondary efficacy endpoint, Cumulative Reactive Dose
(CRD), will also be evaluated in EPITOPE to establish the total quantity of
peanut protein that triggers patient reactions at month 12 of active treatment
versus placebo. Serological markers will also be measured at baseline, 3, 6, and
12 months in order to characterize the immunological changes in patients.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release may contain forward-looking statements and estimates,
including statements regarding the potential of Viaskin Peanut. These forward-
looking statements and estimates are not promises or guarantees and involve
substantial risks and uncertainties. At this stage, the products of the Company
have not been authorized for sale in any country. Among the factors that could
cause actual results to differ materially from those described or projected
herein include uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals and the risk that
historical clinical results in one patient population may not be predictive of
future clinical trial results in different patient populations. A further list
and description of these risks, uncertainties and other risks can be found in
the Company's regulatory filings with the French Autorité des Marchés
Financiers, the Company's Securities and Exchange Commission filings and
reports, including in the Company's Annual Report on Form 20-F for the year
ended December 31, 2016 and future filings and reports by the Company. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of the date
hereof. Other than as required by applicable law, DBV Technologies undertakes no
obligation to update or revise the information contained in this Press Release.
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2124917/810917.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.08.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 554934
Anzahl Zeichen: 9523
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 285 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
